| 000 | 01090 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250515171959.0 | ||
| 264 | 0 | _c20090601 | |
| 008 | 200906s 0 0 eng d | ||
| 022 | _a1526-632X | ||
| 024 | 7 |
_a10.1212/01.wnl.0000347020.85704.36 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSteiner, Israel | |
| 245 | 0 | 0 |
_aQuantitative risk-benefit analysis of natalizumab. _h[electronic resource] |
| 260 |
_bNeurology _cMay 2009 |
||
| 300 |
_a1791-2; author reply 1791-2 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukoencephalopathy, Progressive Multifocal _xetiology |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xcomplications |
| 650 | 0 | 4 | _aNatalizumab |
| 650 | 0 | 4 | _aRisk Factors |
| 773 | 0 |
_tNeurology _gvol. 72 _gno. 20 _gp. 1791-2; author reply 1791-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/01.wnl.0000347020.85704.36 _zAvailable from publisher's website |
| 999 |
_c18878497 _d18878497 |
||